# Geoffrey von Maltzahn

> Geoffrey von Maltzahn is the co-founder and CEO of Lila Sciences, a Cambridge company building what it calls scientific superintelligence: AI plus robotic labs that run the scientific method autonomously. A general partner at Flagship Pioneering, he has founded or co-founded a string of companies including Generate:Biomedicines, Tessera Therapeutics, Indigo Agriculture, Sana Biotechnology, Seres Therapeutics and Quotient Therapeutics, which together carry more than $10 billion in market value. He holds a PhD from the Harvard-MIT Division of Health Sciences and Technology and is named on more than 200 patents.

- **Role:** Co-Founder and CEO at Lila Sciences
- **Organizations:** Lila Sciences, Flagship Pioneering, Generate:Biomedicines, Tessera Therapeutics, Quotient Therapeutics, Indigo Agriculture, Sana Biotechnology, Seres Therapeutics
- **From:** Arlington, Texas, United States
- **Nationality:** American
- **Education:** High school diploma, Thomas Jefferson High School for Science and Technology, SB, Chemical Engineering, Massachusetts Institute of Technology (MIT), MS, Bioengineering, University of California, San Diego, PhD, Biomedical Engineering and Medical Physics (advisor Sangeeta Bhatia), Harvard-MIT Division of Health Sciences and Technology
- **Known for:** Co-founded companies with more than $10 billion in aggregate public and private market capitalization., Named inventor on more than 200 patents and patent applications., Co-authored more than 20 peer-reviewed scientific articles.

## Career timeline

- **2009** — Joined Flagship Pioneering in Cambridge, Massachusetts.
- **2009** — Won the Lemelson-MIT Student Prize and the Collegiate Inventors Competition Graduate Prize.
- **2016** — Co-founded Indigo Agriculture, applying plant microbiome science to crops.
- **2018** — Co-founded Generate:Biomedicines and Tessera Therapeutics.
- **2020** — Became a general partner at Flagship Pioneering.
- **2023** — Co-founded Quotient Therapeutics with Jacob Rubens.
- **2025** — Flagship publicly unveiled Lila Sciences with him as co-founder and CEO.
- **2025** — Lila raised a $235M Series A at roughly $1.23B valuation, reaching unicorn status with Nvidia backing.

## Achievements

- Co-founded companies with more than $10 billion in aggregate public and private market capitalization.
- Named inventor on more than 200 patents and patent applications.
- Co-authored more than 20 peer-reviewed scientific articles.
- Founding CEO of Generate:Biomedicines, Tessera Therapeutics, Quotient Therapeutics and Indigo Agriculture.
- Co-founder of Sana Biotechnology (Nasdaq: SANA) and Seres Therapeutics (Nasdaq: MCRB).
- Lila Sciences reached unicorn status less than a year after founding.
- Lemelson-MIT Student Prize (2009).
- National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize (2009).

## Latest updates

- **2025-09** — Lila Sciences raised a $235 million Series A at roughly a $1.23 billion valuation, gaining unicorn status with new backing from Nvidia.
- **2025-03** — Flagship Pioneering publicly unveiled Lila Sciences and its mission to build scientific superintelligence.

## Links

- Website: https://lila.ai
- LinkedIn: http://www.linkedin.com/in/geoffrey-von-maltzahn-7a6b755a
- YouTube: https://www.youtube.com/watch?v=03q438FF0Is

---

Profile page: https://yespress.io/geoffrey-maltzahn
Published by YesPress — https://yespress.io
Last updated: 2026-07-01